Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma

Inclusion Criteria: * Histologically confirmed stage IIIC or stage IV melanoma * Measurable disease * Age 18 or older * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * No radiation therapy within 2 weeks prior to first vaccine administration * No chemotherapy within 4 weeks prior to first vaccine administration * No steroid therapy within 4 weeks prior to first vaccine administration * No surgery within 10 days prior to first vaccine administration * Patient's written informed consent * Patient's ability to comply with the visit schedule and assessments required by the protocol * Adequate organ function (measured within a week of beginning treatment): * White blood count (WBC) \> 3,000/mm\^3 and absolute neutrophil count (ANC) \>1500/mm\^3 * Platelets \> 100,000/mm\^3 * Hematocrit \> 25% and Hgb \> 8 g/dL * Bilirubin \< 2.0 mg/dL * Creatinine \< 2.0 mg/dL, or creatinine clearance \> 60 mL/min Exclusion Criteria: * Symptomatic or untreated brain metastasis * Any serious ongoing infection * Current corticosteroid or other immunosuppressive therapy * Any other pre-existing immunodeficiency condition (including known HIV infection) * Pregnant or lactating women -- Patients in reproductive age must agree to use contraceptive methods for the duration of the study (\*A pregnancy test will be obtained before treatment) * ECOG performance status of 2, 3, or 4 * Any second active primary cancer